Navigation Links
Endocare Stock to Commence Trading on NASDAQ
Date:10/9/2007

IRVINE, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Endocare, Inc. (OTC Bulletin Board: ECRE), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has been approved for listing on NASDAQ. The Company's common stock will commence trading on The NASDAQ Capital Market under the symbol "ENDO" beginning tomorrow, October 10, 2007.

Craig T. Davenport, Endocare's Chief Executive Officer stated, "Our listing on NASDAQ is a significant milestone for Endocare, marking the completion of a long turnaround process. We believe that the NASDAQ listing should help us attract a broader audience of potential investors, resulting in a more liquid security and enhanced stockholder value over time."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements relating to the Company's listing on The NASDAQ Capital Market. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the U.S. Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the listing of the Company's common stock on The NASDAQ Capital Market. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact: For Additional Information:

Matt Clawson Len Hall Craig T. Davenport, CEO

Allen & Caron, Inc. Allen & Caron, Inc. Michael R. Rodriguez, CFO

(949) 474-4300 (949) 474-4300 Endocare, Inc.

matt@allencaron.com len@allencaron.com (949) 450-5400


'/>"/>
SOURCE Endocare, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
2. Risk of deep vein thrombosis less in people who were flight stockings when flying
3. Health and Human Services stockpiles 20 million bird flu Vaccines
4. Rich countries stock piling anti flu drugs with no stocks available for poor countries
5. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
6. Bird Flu Threat Prompts Stockpiling Of Food And Medicine In America
7. Wake Up Call: U.N Takes Stock to Curb Fake Medicines Racket
8. Bird flu: the threat causes lowering in poultry stocks
9. OpenMED Nominated For Stockholm Challenge 2006 Award
10. Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings
11. Time is ripe to take stock of depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a South African company ... available for purchase on RevNutrition.com, a popular website specializing in sales of nutritional products. ... in ancient India and Siam. It spread across Asia and Africa quickly, and today ...
(Date:4/24/2017)... HOUSTON, TEXAS (PRWEB) , ... April 24, 2017 ... ... service (SaaS) based healthcare compliance and credentialing solutions, today announced that Kyle Allain ... Allain leads symplr’s Cactus Provider Management sales and operations, including provider, payor and ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, up to ... approximately 25,000 of them will be malignant.(1) As research into precision medicine continues, ... healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that ...
(Date:4/24/2017)... , ... April 24, 2017 , ... Rod Burkett, CEO ... Housing News website. , Rod has been at the forefront of Gardant since it ... As CEO, Rod has overseen the opening of more than 40 new senior living ...
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... 2017 Halo Labs announces the launch of ... system called the Horizon at PEGS 2017 in ... system analyzes sub visible particulate matter in biopharmaceutical samples ... as early as candidate selection and pre-formulation. ... research organization Elion Labs for system validation. ...
(Date:4/20/2017)... MARLBOROUGH, Mass. , April 20, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... new data from the Company,s consumer product development ... technology, at the Society for Investigative Dermatology (SID) ... is to advance and promote the sciences relevant ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: